UK markets open in 6 hours 48 minutes
  • NIKKEI 225

    27,999.96
    0.00 (0.00%)
     
  • HANG SENG

    20,003.44
    -42.33 (-0.21%)
     
  • CRUDE OIL

    90.34
    -0.16 (-0.18%)
     
  • GOLD FUTURES

    1,810.10
    -2.20 (-0.12%)
     
  • DOW

    32,774.41
    -58.13 (-0.18%)
     
  • BTC-GBP

    19,140.92
    -681.38 (-3.44%)
     
  • CMC Crypto 200

    537.36
    -19.99 (-3.59%)
     
  • ^IXIC

    12,493.93
    -150.53 (-1.19%)
     
  • ^FTAS

    4,129.39
    -3.43 (-0.08%)
     

atai Life Sciences to Announce Second Quarter 2022 Financial Results and Business Update

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Atai Life Sciences AG
Atai Life Sciences AG

NEW YORK and BERLIN, Aug. 01, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, plans to announce its second quarter 2022 financial results and business update on Monday, August 15, 2022.

A video interview with atai management will be available at 8:30 a.m. (ET) at https://vimeo.com/atailifesciences. The archived video interview will be available in the “Events” section of the atai website at https://www.atai.life/.

About atai Life Sciences

atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, atai is dedicated to acquiring, incubating, and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.

atai's business model combines funding, technology, scientific, and regulatory expertise with a focus on innovative compounds, including psychedelic therapy and other drugs with differentiated safety profiles and therapeutic potential. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies to achieve clinically meaningful and sustained behavioral change in mental health patients.

atai's vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. For more information, please visit https://www.atai.life/.

Contact Information

Investor Contact:
Greg Weaver
Chief Financial Officer
Email: IR@atai.life

Media Contact:
Allan Malievsky
Senior Director, External Affairs
Email: allan@atai.life


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting